0001209191-17-003757.txt : 20170113 0001209191-17-003757.hdr.sgml : 20170113 20170113194819 ACCESSION NUMBER: 0001209191-17-003757 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170111 FILED AS OF DATE: 20170113 DATE AS OF CHANGE: 20170113 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cascadian Therapeutics, Inc. CENTRAL INDEX KEY: 0001412067 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 260868560 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2601 FOURTH AVENUE STREET 2: SUITE 500 CITY: SEATTLE STATE: WA ZIP: 98121 BUSINESS PHONE: (206) 801-2100 MAIL ADDRESS: STREET 1: 2601 FOURTH AVENUE STREET 2: SUITE 500 CITY: SEATTLE STATE: WA ZIP: 98121 FORMER COMPANY: FORMER CONFORMED NAME: Oncothyreon Inc. DATE OF NAME CHANGE: 20070927 FORMER COMPANY: FORMER CONFORMED NAME: Biomira CORP DATE OF NAME CHANGE: 20070911 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Myers Scott Dunseth CENTRAL INDEX KEY: 0001356256 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33882 FILM NUMBER: 17528916 MAIL ADDRESS: STREET 1: C/O ONOTHYREON INC. STREET 2: 2601 4TH AVENUE, SUITE 500 CITY: SEATTLE STATE: WA ZIP: 98121 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-01-11 0 0001412067 Cascadian Therapeutics, Inc. CASC 0001356256 Myers Scott Dunseth C/O CASCADIAN THERAPEUTICS, INC. 2601 4TH AVE., SUITE 500 SEATTLE WA 98121 1 1 0 0 President and CEO Stock Option (right to buy) 4.64 2017-01-11 4 A 0 190000 0.00 A 2027-01-11 Common Stock 190000 190000 D Restricted Share Unit (RSU) 2017-01-11 4 A 0 42000 0.00 A 2021-01-11 Common Stock 42000 42000 D The option vests and is exercisable at the rate of 1/4th of the total shares on January 11, 2018 and then 1/48th of the total shares vest and are exercisable monthly thereafter, with 100% vested and exercisable on January 11, 2021, subject to the holder's continued employment with the issuer on each vesting date. Approximately 67% of each RSU represents a contingent right to receive approximately 0.67 share of the issuer's Common Stock upon vesting and approximately 33% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate the holder's satisfaction of U.S. federal tax obligations in connection with the vesting of the RSUs. Twenty-five percent of the shares underlying the RSU vest on each of January 11, 2018, January 11, 2019, January 11, 2020 and January 11, 2021, subject to the holder's continued employment with the issuer on each vesting date. /s/ Julia M. Eastland as attorney-in-fact for Scott D. Myers 2017-01-13